According to filings with the U.S. Securities and Exchange Commission, RevOpsis Therapeutics is raising $7,895,004.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Ramanath Bhandari played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About RevOpsis Therapeutics
Unlike the traditional bispecific antibody technology, our proprietary next-generation novel Surrobody platform holds the master key for efficient and accelerated drug discovery and development of bispecifics. RO-101 is our lead product candidate, utilizing our proprietary Surrobody technology to target two clinically validated targets with a single injection to potentially treat highly prevalent chronic retinal diseases such as wAMD and DR. It is a fully human bispecific surrobody designed to inactivate VEGF-A and Ang-2 at nanomolar affinities. In-vitro experiments demonstrated superior anti-angiogenic activity for RO-101 when compared to current standard of care, aflibercept (Eylea). In a head-to-head analytical biochemistry assay (ELISA), RO-101 was 100 times more effective in binding Ang-2 versus the recently approved Faricimab-svoa (Vabysmo). We believe RO-101 is a potentially best-in-class product candidate that is intended to provide extended disease remission and optimal clinical outcomes in a majority of patients suffering with wAMD and DR.

To learn more about RevOpsis Therapeutics, visit http://revopsis.com/

Contact:
Ramanath Bhandari, Chief Executive Officer
646-221-5178
https://www.linkedin.com/in/ramanath-bhandari-9a7741178/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.